The Clorox Company disclosed its IGNITE outlook targeting **3%–5% sales growth**, **adjusted EBIT margin expansion of 25–50 bps**, and **free cash flow of 11%–13%**. It also highlighted variation in FY25 performance by segment, with net sales weighted toward **Health & Wellness (38%)** and **Household (28%)**, versus smaller contributions from **Lifestyle (15%)** and **International (18%)**.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Clorox Company published the original content used to generate this news brief on February 19, 2026, and is solely responsible for the information contained therein.
Comments